5-imidazolyl-quinolinones, -quinazolinones and -benzo-azepinones as farnesyltransferase inhibitors

被引:31
作者
Angibaud, P
Bourdrez, X
Devine, A
End, DW
Freyne, E
Ligny, Y
Muller, P
Mannens, G
Pilatte, I
Poncelet, V
Skrzat, S
Smets, G
Van Dun, J
Van Remoortere, P
Venet, M
Wouters, W
机构
[1] Johnson & Johnson Pharmaceut Res & Dev, Dept Med Chem, F-27106 Val De Reuil, France
[2] Johnson & Johnson Pharmaceut Res & Dev, Oncol Drug Discovery, Spring House, PA 19477 USA
[3] Johnson & Johnson Pharmaceut Res & Dev, Oncol Discovery Res, B-2340 Beerse, Belgium
[4] Johnson & Johnson Pharmaceut Res & Dev, Preclin Pharmacokinet, B-2340 Beerse, Belgium
[5] Johnson & Johnson Pharmaceut Res & Dev, Drug Evaluat, B-2340 Beerse, Belgium
关键词
D O I
10.1016/S0960-894X(03)00180-X
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The evaluation of structure activity relationships associated with the modification of the R115777 quinolinone ring moiety displaying potent in vitro inhibiting activity is described. (C) 2003 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1543 / 1547
页数:5
相关论文
共 27 条
  • [1] Inhibition of farnesyltransferase increases TGFβ type II receptor expression and enhances the responsiveness of human cancer cells to TGFβ
    Adnane, J
    Bizouarn, FA
    Chen, Z
    Ohkanda, J
    Hamilton, AD
    Munoz-Antonia, T
    Sebti, SM
    [J]. ONCOGENE, 2000, 19 (48) : 5525 - 5533
  • [2] ANGIBAUD PR, 2002, Patent No. 0142296
  • [3] Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules
    Ashar, HR
    James, L
    Gray, K
    Carr, D
    Black, S
    Armstrong, L
    Bishop, WR
    Kirschmeier, P
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (39) : 30451 - 30457
  • [4] RAS GENES
    BARBACID, M
    [J]. ANNUAL REVIEW OF BIOCHEMISTRY, 1987, 56 : 779 - 827
  • [5] BOS JL, 1989, CANCER RES, V49, P4682
  • [6] DER CJ, 1991, CANCER CELL-MON REV, V3, P331
  • [7] End DW, 2001, CANCER RES, V61, P131
  • [8] Farnesyl protein transferase inhibitors and other therapies targeting the ras signal transduction pathway
    End, DW
    [J]. INVESTIGATIONAL NEW DRUGS, 1999, 17 (03) : 241 - 258
  • [9] END DW, UNPUB
  • [10] Feldkamp MM, 1999, INT J CANCER, V81, P118, DOI 10.1002/(SICI)1097-0215(19990331)81:1<118::AID-IJC20>3.0.CO